About Rare Mutations and Fusions in Lung Cancer
Currently, there are 12 DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
New & Upcoming
Latest Updates
-
Precision, Partnership, Purpose: Lung Cancer Highlights from AACR 2026
The American Association for Cancer Research (AACR) Annual Meeting brought together thousands of cancer researchers, clinicians, advocates, and patients in San Diego from April 17... -
Podcast: Making the Most of Your Healthcare Visits
How do you make the most of your visits with your healthcare team? In this episode, lung cancer survivor Bill Morris shares his experience with lung cancer and how he approaches... -
Watch HOPE Summit 2026 Videos
HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well...
Sponsors
